

A growing portfolio of cost-effective
CT and MRI **Generic Contrast Agents.**

Now you have a choice. RSNA 2024 | Booth #3235

DISCOVER MORE



FRESENIUS
KABI

AJNR

Dramatically Reducing Imaging-to-Recanalization Time in Acute Ischemic Stroke: Making Choices

M. Goyal and M.A. Almekhlafi

AJNR Am J Neuroradiol published online 21 June 2012
<http://www.ajnr.org/content/early/2012/06/21/ajnr.A3215.citation>

This information is current as
of November 22, 2024.

EDITORIAL

Dramatically Reducing Imaging-to-Recanalization Time in Acute Ischemic Stroke: Making Choices

In the treatment of acute stroke, we are reasonably sure of certain issues. These are the following:

1) Dead brain is dead brain. Infarcted brain tissue cannot be salvaged.¹ So far, no attempts at neuroprotection have been successful.² These issues are relevant from the perspective of the detection of irreversibly damaged brain tissue. Various imaging methods have been shown to be reasonably good at detecting dead tissue (DWI,³ Alberta Stroke Program Early CT Score [ASPECTS] on NCCT,⁴ low CBV or very low CBF on CT/MR perfusion,⁵ and so forth). Of these, DWI is the most sensitive and specific, though not perfect.⁶

2) Hyperacute stroke is a dynamic process. In the absence of recanalization, it has been well demonstrated that for most strokes, the ischemic core grows to incorporate the penumbra with time.⁷ While exuberant collaterals might prolong the penumbral tissue survival, our ability to sustain these with medical intervention has not been successful.⁸

3) Recanalization helps. This has been the basis of not only IV thrombolytic therapy but also mechanical intra-arterial (IA) approaches.⁹

4) No form of intervention, chemical or mechanical, is without risk.¹⁰⁻¹²

5) Imaging is a snapshot in time of a dynamic process.

On the other hand, there are issues that we do not fully understand. The key ones are the following:

1) What is the rate of infarct progression? At what rate does penumbra turn into core? Which factors influence this rate? How much time does one have before recanalization becomes futile?

2) Do collaterals evolve with time and to what extent? Changes in the length and diameter of collaterals have been demonstrated in animal models, but this process is less well-understood in humans.

3) What is the role of spreading depression?¹³ This loss of electrical activity and the associated biochemical and structural alterations, classically described in migraine, may have a role in the ischemic core progression.¹⁴

4) How does selective vulnerability of neuronal tissue influence patient outcome? It is well-known that certain brain regions are more susceptible to ischemia than others, but the mechanisms underlying this vulnerability and their effect on infarct progression and patient outcome are not understood.¹⁵

5) What is the best measure of penumbra? This question assumes that the tissue measured conforms to the penumbra definition: nonfunctioning tissue that is currently viable but will die unless blood supply is resumed quickly (please note that in this definition, there is no mention of how much time there is before penumbra dies).¹⁶

Other relevant issues are related to the imaging technique that is the best, most appropriate, most widely available, and easiest to interpret. At one end of the spectrum is NCCT,

which is sufficient for triage and decision-making and has been extensively studied.¹⁷ Most large randomized controlled trials, including the National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group,¹⁸ European Cooperative Acute Stroke Study,¹⁹ and International Management of Stroke-III,²⁰ used NCCT. At the other end of the spectrum are DWI, perfusion, and MRA.⁶ MR imaging has been used in a number of trials including the Desmoteplase in Acute Ischemic Stroke Trial,^{21,22} the Echoplanar Imaging Thrombolytic Evaluation Trial,²³ the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study,²⁴ and the ongoing Magnetic Resonance and Recanalization of Stroke Clots Using Embolectomy trial.

These modalities have pros and cons, but most notably, NCCT has the big advantage of convenience (fast, available around the clock, no contraindications) and is supported by evidence from acute stroke trials, while MR imaging is sensitive to identifying the site and extent of early ischemic changes but requires screening for potential contraindications and requires patient cooperation (difficult in an acute stroke setting). In our opinion, the biggest limitation of the MR imaging-based approach is the amount of time it takes to perform the studies. Some centers have developed protocols lasting only 5–7 minutes,²⁵ but the total time required from when the test is ordered until all data are postprocessed can exceed 30 minutes.²⁶

Recently, there have been significant advances in mechanical IA therapy (the Merci retriever, Concentric Medical, Mountain View, California; the Penumbra System, Penumbra, Alameda, California; Solitaire, ev3, Irvine, California; and so forth).²⁷ Studies using these devices have consistently shown rates of recanalization approaching 90%.²⁸ These devices are being used in severe strokes and in proximal artery occlusions. However, these high recanalization rates are not reflected in the rate of functional recovery, which still lags behind.

Of all mentioned items, in our opinion, these are clear:

- 1) Most infarcts grow over time.
- 2) We are not good at determining their rate of growth.
- 3) Early recanalization prevents infarct growth and can lead to better patient prognosis.
- 4) We are reasonably good at determining the initial size of the infarct core.
- 5) Newer devices achieve high recanalization rates in patients with large-vessel occlusions.

If we accept these statements as true, we can infer that as soon as a patient is suspected of having an acute ischemic stroke with a small core and proximal vessel occlusion, every attempt should be made to minimize imaging-to-recanalization time because this affects infarct growth. Here, we suggest a protocol to achieve an imaging-to-recanalization time of <60 minutes. After a hemorrhage is excluded, the following steps could be taken:

- 1) CTA (5 minutes)
- 2) CT perfusion and postprocessing (15 minutes)
- 3) Brain MR imaging (45 minutes; this includes ruling out contraindications, doing necessary paperwork, taking the patient to MR imaging, achieving patient cooperation, performing the imaging, and postprocessing). Even though there would be some variability from center to center, in most cen-

ters, this protocol takes approximately 45 minutes, leaving only 15 minutes to achieve recanalization.

As soon as imaging is assessed, one must perform the following:

- 1) Start IV tPA if appropriate (10 minutes).
- 2) Obtain consent for IA therapy in case it will be necessary (10 minutes).
- 3) Plan for DSA.
- 4) Assess patient cooperation and involve anesthesia if necessary (20 minutes).
- 5) Prep the patient (10 minutes).
- 6) Obtain vascular access and perform DSA (10 minutes).
- 7) Achieve recanalization (10 minutes).

To achieve recanalization in <60 minutes, one must make choices and compromises. Is MR imaging really needed? It could be argued that without MR imaging, it is impossible to determine core size precisely. While this is correct, what degree of precision is required? The degree of core estimation on NCCT by using the ASPECTS methodology has been well-tested and validated.²⁹ Web sites are available to aid in becoming proficient at using this system (aspectsinstroke.com). Optimization of the newer CT scanners allows excellent gray-white differentiation without significant increases in radiation doses.³⁰

Is CTA really needed? We believe that it is worth the time spent. Overall, little additional time is needed if the patient is already on the CT table. While there are concerns regarding contrast-induced nephropathy, it has been shown that these are not significant.³¹ Benefits of CTA include the following: 1) confirming the presence of proximal occlusion, 2) core assessment on CTA source images,^{29,32} 3) collateral circulation assessment,³³ and 4) displaying arch anatomy that may facilitate DSA. Other benefits include ruling out possible contraindications to IA therapy, such as unstable aortic thrombus, and documenting the presence of arterial dissections.

Is CT perfusion really needed? While it helps to define core size, estimate penumbra presence and size, and determine the presence of collateral circulation, we suggest that it is not worth the time spent on it.³⁴ There is a lack of standardization of protocols and postprocessing techniques across vendors.³⁵ The best parameter to define penumbra is not clear,⁵ and there is no consensus about it. Perfusion does not answer the question of the rate of infarct progression.³⁶ Radiation dose may be an issue in younger patients, especially if whole-brain coverage is obtained.³⁷ Patient cooperation is important for image quality.

Is anesthesia really needed? This easily adds 20–25 minutes, leaving only 40–45 minutes to achieve recanalization. Additionally, a number of recent publications warn against the potential harm of general anesthesia.³⁸ While some interventionists think that performing these complex procedures without it may increase complication rates, this is not true in our experience in which conscious sedation is adequate.

Is a complete diagnostic DSA really needed? While it has merits (assessment of collaterals and so forth), it takes time, easily 10 minutes and, in our opinion, provides very little additional information. We favor going straight to the vessel of interest.

One could also argue that an IA treatment approach is not necessary. However, multiple studies have shown poor recan-

alization rates with IV tPA alone in proximal occlusions.⁹ It is difficult to precisely determine how long it takes to achieve recanalization with IV approaches. Moreover, if the aim is to achieve an imaging-to-recanalization time of <60 minutes, one may need to try multiple approaches simultaneously. Safety is paramount, and one should not gain efficiency at the expense of safety.

The issue of a well-informed consent in emergency situations still remains controversial.³⁹ While a stroke neurologist discusses the consent, the interventionist should proceed with preparation of materials, assuming that the consent will be obtained. Obtaining consent for inclusion in a trial can slow down the process, especially if the procedure itself is being tested.

Therefore, in our opinion, in patients with clinically large ischemic strokes, focusing on imaging-to-recanalization time makes the most sense. We think that spending time on CTA is worth the information it provides. MR imaging, while excellent at determining core, takes too long. The verdict on CT perfusion is not clear, but we favor avoiding it. General anesthesia may be avoided unless absolutely necessary, and a complete diagnostic angiogram may not be required. Mechanical approaches to recanalization may be preferable to systemic treatments.

References

1. Heiss WD, Rosner G. Functional recovery of cortical neurons as related to degree and duration of ischemia. *Ann Neurol* 1983;14:294–301
2. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. *Ann Neurol* 2007;61:396–402
3. Pierpaoli C, Righini A, Linfante I, et al. Histopathologic correlates of abnormal water diffusion in cerebral ischemia: diffusion-weighted MR imaging and light and electron microscopic study. *Radiology* 1993;189:439–48
4. Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group Alberta Stroke Programme Early CT Score. *Lancet* 2000;355:1670–74
5. Dani KA, Thomas RG, Chappell FM, et al. Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. *Ann Neurol* 2011;70:384–401
6. Schellinger PD, Bryan RN, Caplan LR, et al. Evidence-based guideline: the role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke—report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2010;75:177–85
7. Boysen G, Christensen H. Early stroke: a dynamic process. *Stroke* 2001;32:2423–25
8. Verro P, Chow M. Prolonged dependence of ischemic penumbra on induced hypertension. *Neurologist* 2009;15:296–97
9. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. *Stroke* 2007;38:967–73
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008;359:1317–29
11. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke—PROACT Investigators. *Prolyse in Acute Cerebral Thromboembolism*. *Stroke* 1998;29:4–11
12. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke* 2008;39:1205–12
13. Takano K, Latour LL, Formato JE, et al. The role of spreading depression in focal ischemia evaluated by diffusion mapping. *Ann Neurol* 1996;39:308–18
14. Strong AJ, Anderson PJ, Watts HR, et al. Peri-infarct depolarizations lead to loss of perfusion in ischaemic gyrencephalic cerebral cortex. *Brain* 2007;130(pt 4):995–1008
15. Dijkhuizen RM, Knollemans S, van der Worp HB, et al. Dynamics of cerebral tissue injury and perfusion after temporary hypoxia-ischemia in the rat: evidence for region-specific sensitivity and delayed damage. *Stroke* 1998;29:695–704
16. Heiss WD. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke: the Johann Jacob Wepfer award 2011. *Cerebrovasc Dis* 2011;32:307–20
17. von Kummer R, Meyding-Lamade U, Forsting M, et al. Sensitivity and prog-

- nostic value of early CT in occlusion of the middle cerebral artery trunk. *AJNR Am J Neuroradiol* 1994;15:9–15, discussion 16–18
18. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med* 1995;333:1581–87
 19. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. *Lancet* 1998;352:1245–51
 20. Khatri P, Hill MD, Palesch YY, et al. Methodology of the Interventional Management of Stroke III Trial. *Int J Stroke* 2008;3:130–37
 21. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke* 2005;36:66–73
 22. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. *Lancet Neurol* 2009;8:141–50
 23. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurol* 2008;7:299–309
 24. Marks MP, Olivot JM, Kemp S, et al. Patients with acute stroke treated with intravenous tPA 3–6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. *Radiology* 2008;249:614–23
 25. Graves MJ, U-King-Im J, Howarth S, et al. Ultrafast magnetic resonance imaging protocols in stroke. *Expert Rev Neurother* 2006;6:921–30
 26. Hand PJ, Wardlaw JM, Rowat AM, et al. Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient related difficulties. *J Neurol Neurosurg Psychiatry* 2005;76:1525–27
 27. Baker WL, Colby JA, Tongbram V, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. *Ann Intern Med* 2011;154:243–52
 28. Costalat V, Machi P, Lobotesis K, et al. Rescue, combined, and stand-alone thrombectomy in the management of large vessel occlusion stroke using the Solitaire device: a prospective 50-patient single-center study: timing, safety, and efficacy. *Stroke* 2011;42:1929–35
 29. Lin K, Rapalino O, Law M, et al. Accuracy of the Alberta Stroke Program Early CT Score during the first 3 hours of middle cerebral artery stroke: comparison of noncontrast CT, CT angiography source images, and CT perfusion. *AJNR Am J Neuroradiol* 2008;29:931–36
 30. Rapalino O, Kamalian S, Payabvash S, et al. Cranial CT with adaptive statistical iterative reconstruction: improved image quality with concomitant radiation dose reduction. *AJNR Am J Neuroradiol* 2012;33:609–15
 31. Krol AL, Dzialowski I, Roy J, et al. Incidence of radiographic nephropathy in patients undergoing acute stroke computed tomography angiography. *Stroke* 2007;38:2364–66
 32. Schramm P, Schellinger PD, Fiebach JB, et al. Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. *Stroke* 2002;33:2426–32
 33. Menon BK, Smith EE, Modi J, et al. Regional leptomeningeal score on CT angiography predicts clinical and imaging outcomes in patients with acute anterior circulation occlusions. *AJNR Am J Neuroradiol* 2011;32:1640–45
 34. Gupta R, Horev A, Wisco D, et al. Abstract 207: CT perfusion increases time to reperfusion and may not enhance patient selection for endovascular reperfusion therapies in acute ischemic stroke. *Stroke* 2012;43:A207
 35. Konstas AA, Lev MH. CT perfusion imaging of acute stroke: the need for arrival time, delay insensitive, and standardized postprocessing algorithms? *Radiology* 2010;254:22–25
 36. Heiss WD, Kracht LW, Thiel A, et al. Penumbra probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. *Brain* 2001;124(pt 1):20–29
 37. Eastwood JD, Lev MH, Wintermark M, et al. Correlation of early dynamic CT perfusion imaging with whole-brain MR diffusion and perfusion imaging in acute hemispheric stroke. *AJNR Am J Neuroradiol* 2003;24:1869–75
 38. Davis MJ, Menon BK, Baghirzada LB, et al. Anesthetic management and outcome in patients during endovascular therapy for acute stroke. *Anesthesiology* 2012;116:396–405
 39. Biros MH, Lewis RJ, Olson CM, et al. Informed consent in emergency research: consensus statement from the Coalition Conference of Acute Resuscitation and Critical Care Researchers. *JAMA* 1995;273:1283–87

M. Goyal

M.A. Almekhlafi

Departments of Diagnostic Imaging and Clinical Neurosciences

University of Calgary

Calgary, Alberta, Canada

<http://dx.doi.org/10.3174/ajnr.A3215>